CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Acetyl-L-carnitinedrug
Likely dose
Acetyl-L-carnitine 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01695317
NCT01695317Phase 4Completed

Effect of Acetyl-L-carnitine in Migraine - a Randomized, Double-blind Placebo Controlled Study

Norwegian University of Science and Technology·interventional·Posted Sep 27, 2012·Updated Apr 13, 2022

In Brief

A Phase 4 clinical trial evaluating Acetyl-L-carnitine for Migraine. Completed, enrolled 72 participants across 1 site.

Detailed Summary

Traditionally, beta blockers have been used for migraine prophylaxis, but in later years also antiepileptic drugs. Contraindications and side effects have to some degree limited their use, and new prophylactics that can be used by most migraine sufferers and with little side effects are in demand. One product that may seem to fulfill these requirements is Acetyl-L-carnitine, which is a dietary supplement and naturally occurs in plants and animals. L-carnitine is necessary for fatty-acid metabolism and energy production. To our knowledge, no placebo-controlled studies have previously evaluated the efficacy of Acetyl-L-carnitine in adults with migraine. The aims of the present study is to evaluate the efficacy of Acetyl-L-carnitine as a prophylaxis in migraine patients

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesNorway
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 27, 2012
Enrollment StartApr 1, 2013
Primary CompletionJul 1, 2014
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.8 years ago

Interventions

Acetyl-L-carnitinedrug

Week 1: 500 mg x 3, Week 2-12: 500 mg x 6